Drug intelligence / Profile preview

WGc-0301

Development stage: Unknown
Lead developer: Chengdu Weisijin Biopharmaceutical Technology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

WGc-0301 is an investigational mRNA-based cancer vaccine developed by WestGene (WestGene Biopharma) for the treatment of solid tumors. As part of WestGene's tumor treatment vaccine platform, WGc-0301 is designed to stimulate a targeted anti-tumor immune response by delivering genetic instructions for tumor-associated antigens. The vaccine aims to prompt the patient's immune system to recognize and eliminate malignant cells across various solid tumor types. Currently, the drug is in early-stage clinical development, having reached the Phase 1/Investigational New Drug (IND) stage.

Beyond the preview

Go deeper on WGc-0301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WGc-0301.

Explore the full profile